Autoimmune nodopathies: a clinical review

Area of Science:

• Neurology
• Immunology
• Peripheral Nervous System Disorders

Background:

• Autoimmune nodopathies are a distinct subgroup of peripheral neuropathies.
• They are characterized by autoantibodies targeting nodal and paranodal proteins, disrupting the node of Ranvier.
• Unlike CIDP, they do not involve demyelination and are recognized in recent guidelines.

Purpose of the Study:

• To differentiate autoimmune nodopathies from CIDP.
• To highlight the clinical presentation, diagnostic methods, and treatment strategies for autoimmune nodopathies.
• To emphasize the importance of recognizing these conditions for effective patient management.

Main Methods:

• Identification of autoantibodies targeting neurofascin-155 (NF155), contactin-1 (CNTN1), and Contactin-associated protein 1 (Caspr1).
• Clinical assessment of patients presenting with severe distal-dominant sensorimotor neuropathy, sensory ataxia, and tremor.
• Electrophysiological studies and correlation of antibody titers with clinical severity.

Main Results:

• Autoimmune nodopathies account for 5-10% of CIDP-diagnosed patients.
• Patients present with severe sensorimotor neuropathy, ataxia, tremor, and sometimes glomerulonephritis.
• IgG4 subclass autoantibodies are common, suggesting pathogenicity without complement activation.
• Pan-neurofascin autoantibodies lead to severe neuropathy requiring intensive care.

Conclusions:

• Autoimmune nodopathies require specific diagnostic approaches, including autoantibody detection.
• Standard CIDP treatments are often ineffective; plasma exchange and B cell therapies show promise.
• Early recognition and tailored management are essential for improving outcomes in autoimmune nodopathies.